As the classification of mental disorders advances towards a disease model as promoted by the National Institute of Mental Health (NIMH) Research Domain Criteria (RDoC), there is hope that a more thorough neurobiological understanding of mental illness may allow clinicians and researchers to determine treatment efficacy with less diagnostic variability. This paradigm shift has presented a variety of ethical issues to be considered in the development of psychiatric drugs. These challenges are not limited to informed consent practices, industry funding, and placebo use. The consideration for alternative research models and quality of research design also present ethical challenges in the development of psychiatric drugs. The imperatives to create valid and sound research that justify the human time, cost, risk and use of limited resources must also be considered. Clinical innovation, and consideration for special populations are also important aspects to take into account. Based on the breadth of these ethical concerns, it is particularly important that scientific questions regarding the development of psychiatric drugs be answered collaboratively by a variety of stakeholders. As the field expands, new ethical considerations will be raised with increased focus on genetic markers, personalized medicine, patientcentered outcomes research, and tension over funding. We suggest that innovation in trial design is necessary to better reflect practices in clinical settings and that there must be an emphasized focus on expanding the transparency of consent processes, regard for suicidality, and care in working with special populations to support the goal of developing sound psychiatric drug therapies.
Introduction: a brief overview of ethical issues in clinical psychiatric research
The use of psychotropic medications to treat individuals with psychiatric disorders has become one of the mainstays of treatment in the modern era. The advent of pharmacological treatments in the discipline of psychiatry began in the late 1950's with the introduction of chlorpromazine, an antipsychotic medication. Since that time, there have been many phases in the development of pharmaceutical treatments for psychiatric disorders, which have clearly changed the scope and distribution of the fields of psychiatry and neurology. For example, vitamins and antibiotics allowed targeted treatment of psychosis, various dementias, and delirious states (e.g. pellagra, syphilitic encephalitis, cases of Wernicke-Korsakoff Syndrome and alcohol related amnestic disorders). Such treatments radically changed the course of previously incurable mental afflictions. In addition to their curative power, these treatments also provided insight into the pathophysiology of many mental disorders, greatly improving our understanding of these afflictions (Ban, 2001) .
Serendipity, it is argued, has been a powerful source of psychopharmacological discoveries, with insights both in psychopathology and pharmacotherapy (e.g. the discovery of isoniazid's anti-depressive properties in patients with tuberculosis, chlorpromazine's shift from an anesthetic to an antipsychotic, and the depressive effects of reserpine in patients with hypertension; Klein, 2008) . While this review is not aimed at providing a detailed history of the development or use of drugs in psychiatry and neurology, these examples show that early efforts at developing drugs targeting the central nervous system were focused on an increased understanding of complex conditions and the treatment of those conditions. To some extent, many scientific challenges about drug development in psychiatry have not changed much; it is obviously challenging to create a valid scientific hypothesis for disorders that are imperfectly understood from a pathophysiological perspective and classified in ways that are often debated if not polemic in the profession and in the population.
This state of affairs might change as mental disorders classification become closer to a disease model as promoted by the NIMH Research Domain Criteria (RDoC) (Casey et al., 2014; Cuthbert and Insel 2013; Morris and Cuthbert, 2012) . The belief is that with better insight into the neurobiology behind the phenomenological manifestations, clinicians and researchers will be able to determine the efficacy of treatments with less diagnostic heterogeneity. But there are thoughtful observers who doubt that psychiatry has the ability to distill these experiences to a basic biological or physiological level to the extent that RDoC proposes (Frances, 2014) . To be sure, this lack of pathophysiological understanding and diagnostic validity also becomes an ethical issue whenever patients/subjects and public resources are to be used to develop and test a drug for the condition in question. Are the science and knowledge worthwhile and valid? Are the risks justified by the quality and utility of the results expected to be gained from the research? Good science is certainly an ethical matter when research is to be conducted with limited resources and exposure to risks for participants. Despite the uncertainties of pathophysiology and etiology of psychiatric disorders, drug development in this field can be both ethical and scientifically productive. Clearly, many psychotic, anxious, depressive and manic individuals do fare better with medication than they would otherwise. And drug development can and does to some extent inform etiological understandings of mental conditions.
Many of the early attempts at studying psychoactive substances in the treatment of psychiatric illnesses could be deemed problematic were they to be presented to a research ethics committees in the present era (Miller, 2014) . Were patients apt to give consent to their involvement in the research? Was there a valid scientific hypothesis or equipoise? What about blinding, randomization, independent review? Were the burdens of research fairly distributed? It seems quite clear that until the 1960s, many patient-subjects, in many settings, were actually deceived into being used for clinical research, including for drug development purposes, while they believed they were receiving individualized clinical care.
After the Second World War, many of the ethical challenges of medical research became more salient. The way psychiatry and medicine could be used by ideology and political power was exposed during the famous Nuremberg trial of physicians under the Nazi government (Lifton, 1986) . There was considerable development of the way medical research was going to be performed after the exposition of those terrible abuses. The Nuremberg code particularly emphasized the importance of informed voluntary consent (Shuster, 1997) . The Declaration of Helsinki was adopted in 1964 and became an international standard (World Medical Association, 2001 ). This was then followed by the Belmont report, which was presented in 1979 and proposed principles to which IRBs still refer today. Interestingly, but sadly, it is often the identification of terrible abuses, scandals or other ethical challenges that paved the way to significant reflections, regulations and policy statements that changed the way clinical research, including that of new drugs in psychiatry, was to be conducted.
The development of drugs in psychiatry remains ethically challenging for several reasons. As scholars have pointed out, many of those challenges are not unique to psychiatric research (Chodoff, 1999) . Psychiatry as a field may be particularly susceptible to ethical criticism, and part of this may relate to high degree of stigma that has and continues to affect the entire discipline. Moreover, individuals suffering from mental disorders are perceived as being particularly vulnerable, and perhaps more so than individuals without such a diagnosis. Psychiatry and the patients seen by psychiatrists are somehow different than the rest of patients in medicine, or that is at least what pervades not only the public's perception but frequently health care professionals, writ large. The gravity of strong emotions and objections to psychiatry as a discipline have given rise to organized groups, such as the anti-psychiatry movement, which criticize and emphasize the discipline's value-laden history, focus on vulnerable populations, the nature of problematic behaviors, and the use of coercion at times. Prior analyses of this topic have been generally focused on human subject protections in the context of clinical trials and have called for a more evidence-based approach to human subject review processes (Frank et al., 2003) . In this review, ethical challenges pertaining to clinical research and drug development generally will be presented in a broad perspective, but with specific attention to how ethical challenges manifest themselves in the context of the development of psychotropic drugs/drugs for psychiatric disorders.
In the current paradigm of bioethics and research ethics, justification for conducting a pharmacologic research investigation, must address a number of key items, including: (i) proving that the research in question is of clinical relevance and/or scientific interest to the population being studied; (ii) demonstrating how the knowledge expected to be gained shall transform clinical management in manner to substantiate the time, energy, and financial and human resources the study demands; (iii) an explanation that rationalizes, on multiple levels, the risks to study participants; (iv) measures in place to protect subjects from coercion, adverse events, and ensure the subject understands the purpose of the study, how the subject might benefit (if at all), and the nature and quality of risks associated with participation in the study. Of course, there are other required elements, but these items are of particular interest in the current discourse. It is important to make a distinction between research whose focus is to study a process or phenomenon in order to elucidate incomplete knowledge or understanding which may not offer participants any direct or indirect benefit, but still advances the discipline of study versus research aimed to determine if something (e.g. a drug) is effective in treating a specific condition. Even in this latter context, the goal of the research is not altruistic -it is to answer what is hopefully a clear, valid, and testable scientific hypothesis. The possibility of benefit to the participants is a secondary matter. Due to a lack of knowledge in understanding exact pathophysiologic mechanisms leading to most psychiatric disorders, medicinal treatments in psychiatry often relieve symptoms or dimensions of manifestations of a disorder without actually curing it. This is a major limitation and introduces a great deal of complexity and uncertainty into a field where human factors already play a significant role in influencing response to treatment and outcomes. The aim of the development of new drugs in psychiatry is not always to provide a novel and superior agent, but often to market a product with a more favorable side effect profile, or provide a superior alternative to the roster of existing medications.
A related matter is the use of medications off-label -i.e. prescribing a pharmaceutical to treat a symptom or disorder for which the drug did not receive official FDA approval. This practice is very frequent in psychiatry, and draws attention to tension between clinical experience of health care providers and psychiatric research. Some drugs may never be studied for a specific indication; perhaps a classical example would be the commonplace use of the sedating anti-depressant trazodone to treat initial and sleep maintenance insomnia, despite it not having FDA approval for that indication and a paucity of studies to support such use (Mendelson, 2005) . Nevertheless, clinical experience continues to drive this trend in psychiatry. Moreover, it is highly unlikely that a randomized, doubled blinded, controlled trial will ever be funded to answer this question. This is largely due to financial reasons (generic form available) and because other questions in the field are more pressing from an academic and industrial perspective.
It has been shown in other medical domains that research subjects often had higher than reasonable hopes from their participation in clinical research (Sulmasy et al., 2010) . Concepts such as therapeutic misconception to clinical trials have also been described (Horng and Grady, 2003; Appelbaum et al., 1987; Lidz and Appelbaum, 2002) . This is a challenge for informed consent that must be explicitly addressed, especially with vulnerable populations. Patients in psychiatry are potentially at increased risk when it comes to ethical clinical research whether they feel some sort of obligation because of the therapeutic relationship they may have with the physician recruiting them, or because they may feel coerced for various reasons.
Financial reward and other incentives are also daunting dilemmas, putting presumably an unfair burden of the risks of research on more vulnerable groups in our society, patients with mental disorders certainly being among them. The fact that participation in research may sometimes be the only way for an individual to actually get the medication s/he needs, raises concern. Conscious and unconscious wishes of potential subjects may have to be explored in certain types of trials in psychiatry. Motivations to participate should presumably be more thoroughly addressed if we are to be certain that therapeutic misconception is not the main reason to put oneself at risk; give time; and go through lengthy and possibly uncomfortable procedures and follow-ups. Therapeutic optimism is not necessarily problematic but these aspects ought to be monitored. It would be interesting to verify how patients in psychiatry or people with mental disorders cluster within those categories.
Recent ethical issues in psychiatric research and use of psychotropic drugs
There are, unfortunately, a number of instances where psychiatric research and drug development have resulted in serious breaches of research ethics, as well as local and federal statutes governing such research. Financial links between physicians and the pharmaceutical industry have become a major concern both nationally and internationally. In this section we describe relatively recent research ethics violations, some of which have received notoriety, for the purpose of elucidating ethical concerns of particular interest in the paradigm of psychiatric research. Later, we address these issues individually and in greater detail.
One of the most common concerns in psychiatric research is whether or not subjects possess the mental capacity to provide voluntary informed consent, and by extension, if it is (ever) appropriate for a substitute decision maker (e.g. legal guardian, spouse, parent, etc.) to provide such consent for a patient who is deemed incapable to make such a decision. Due to the impact of psychiatric disorders on cognitive functioning, there is, and arguably ought to be, a high degree of scrutiny about issues of capacity to consent to treatment, particularly if the treatment is experimental. There is also a related issue of forced treatment, for example, under the auspices of a court order issued by a judge.
This brings us to our first example, which is of some notoriety and has been garnering increasing attention over the last few years. About ten years ago, a patient who suffered from a serious psychotic disorder was ordered to be involuntarily detained and submit to treatment by a supervising psychiatrist at the academic facility where the patient was detained indefinitely pending improvement and response to treatment. So far, there is nothing unusual about this circumstance. However, at some point in his course of the treatment, the patient was enrolled in a research study comparing the effectiveness of different antipsychotic medications, presumably having failed trials of other neuroleptics. Critics have argued that the patient's acceptance to participate in the trial hinged on the patient's perception that he would remain involuntarily detained if he did not participate À in other words if he did not submit to treatment, in this case participation in a clinical trial, the likelihood of his psychiatrist saying that he had improved and could be released, would be adversely affected. It is not clear whether measures were in place to address the appropriateness of proceeding to enroll an involuntarily detained and incompetent patient into a research study. It is also worth noting that the patient's mother had vigorously protested against the patient's inclusion in the research study. This particular case has garnered significant attention as the patient ultimately died from a violent act of suicide, the cause of which continues to be debated. Of note, in 2009, several years after the incident the State of Minnesota passed a law restricting the enrolment of persons under a civil commitment order, into drug trials. Detailed review discovered that the patient did not have an advocate with him at the time he signed the informed consent paperwork to enter the research study. The outcry of many individuals including lawmakers, bioethicists, law professors and the patient's family, collectively exerted enough pressure resulting in an external review (Carlson, 2015;  Office of the Legislative Auditor, 2015; Thomas, 2015) .
In another instance, a 2010 ruling by the United States Department of Justice found the drug maker Astra Zeneca guilty of several serious breaches of federal statutes regarding the marketing of its drug Seroquel, and further cited the drug maker for financial ties it established with physicians to promote Seroquel commercially and academically. The charges levied against Astra Zeneca included violation of the anti-kickback statute, unlawful marketing of the drug and fraudulent marketing of the drug by means of actively encouraging its use to treat several conditions for which it was never studied (and thus did not have FDA approval for these unstudied conditions). Embedded within this practice was the offering of kickbacks to providers who specifically used the drug off-label. While the financial penalty levied against the drug developer was substantial, it cannot remedy the understandable perspective that there is a serious problem of corruption and breach of trust. In the end, Astra Zeneca paid a $520 million fine to settle the case (U.S. Department of Justice, 2010; Wilson, 2010) .
The sponsorship of drug trials and a well-known history of close relationships between pharmaceutical companies and primary investigators, especially clinician-scientists, have also led to a number of ethical questions and concerns. One notable case occurred when a major drug manufacturer and nationally renowned child psychiatrist in the United States established an agreement to study an antipsychotic medication for the treatment of pediatric bipolar disorder. This disorder in itself was (and remains) a vigorously debated diagnostic entity. The physician investigator had failed to report the money (greater than $1 million) that was paid by pharmaceutical companies for his research efforts. The results of the research had a major influence on the field of child psychiatry, sharply impacting both the frequency of diagnosis of pediatric bipolar disorder and the specific use of the study drug to treat that diagnosis (Harris, 2008) . This specific case raised alarming ethical concerns, especially because mechanisms were already in place requiring disclosure by the primary investigators of any and all sources of remuneration paid by pharma or other commercial entities. Moreover, the study was conducted on a particularly vulnerable population consisting of children and adolescents, and the study drug was an antipsychotic, a class of medication known to have a myriad of side effects. While there continues to be debate in the field regarding the diagnosis and treatment of pediatric bipolar disorder, in this case the appearance of impropriety led to questions from federal officials and congressional questions. These types of cases highlight the need for improved ethical practices with psychiatric drug development.
One might argue that the research and marketing practices surrounding psychopharmacology is in a state of crisis. Given the importance of pharmacological treatment and the economic and social costs of psychiatric illness, this very concerning. The development of drugs in psychiatry should be dynamic, based on principles of integrity, and instill hope for patients who are suffering. The lack of ethical considerations, scandals, and loss of trust from the public and regulatory authorities, could prove costly to the field and to patients (Young, 1998; Fava, 2007) . The foregoing examples from Harvard, Minnesota and Astra Zeneca are hardly unique. They are simply among recent examples of the types of ethical questions that emerge in the public space when companies and investigators make choices that run contrary to both formal and informal ethical norms.
Ethics of the present drug development pipeline
A drug goes through many steps while it is developed to become a marketed psychotropic substance. The current drug pipeline presents with many ethical challenges at many levels, from phase one through marketing of the drug in question. A classic debate in clinical research has been that of determining the ethical status of the use of placebo versus active comparators in trials. This debate affects most of the areas of clinical research, but psychiatric disorders may be in an especially delicate situation when it comes to determine whether a study design with placebo is justified or unethical (Roberts et al., 2001; Montgomery, 1999) .
3.1. Should the randomized placebo controlled trial be the gold standard?
Within the evidence-based medicine movement, Randomized Placebo Controlled Trials (RPCT) have become the gold standard (Marks, 2000) . This has become true also in the development of drugs in psychiatry (Miller, 2000) . It might be argued that marketing processes such as the FDA standards have pushed the industry in this direction even when other designs might have been appropriate. At times, placebo controlled trials are not ethically possible to conduct, particularly when serious morbidity or mortality is expected in the absence of the standard proven effective treatment. This is rarely the case in psychiatry, where the risks of untreated illness usually imply the experience of anxiety, depression, psychosis of other types of manifestations associated with the disorder in question. Oftentimes, those symptoms are known and have already been experienced by the patient-subject. In the case of depression, it has been shown that the risks of suicide or suicide attempts were not significantly higher in placebo treated individuals during clinical trials (Khan et al., 2000) . It can also be argued that patients with chronic psychiatric illnesses, who have only experienced partial response to treatments or relapses are well placed to judge whether the risk of temporarily untreated illness are acceptable or not at the outset of a trial, and thus able to decide whether they want to participate or not. What is sometimes harder to determine are the long-term effects and consequences of relapses or that of longer time with untreated illness.
Other reasons why placebo controlled trials are sometimes deemed necessary is the high placebo response for many psychiatric disorders, which can be as high as 30-50 percent in some trials, and the active treatment arm sometimes only 10-20 percent higher. There is also a high rate of negative trials in clinical trials of psychotropic drugs, making it even more interesting to have a placebo arm in any trial, even when there is an active comparator, just to make sure that any treatment was effective at all in that particular trial (Miller, 2000) . If a given active comparator treatment is not clearly consistently effective, it is not possible to actually infer effectiveness if there is no placebo arm. In that case, the trial in question might even be unethical, in so far that no valid conclusion can be drawn from it, thereby making the time, risks and resources unjustified scientifically.
Another argument for the placebo arm is that in the end, it allows for a smaller total number of subject-patients to be exposed to the risk of research than would be required if using a single active arm and trying to measure pre-and post-effects. This is the difference between looking at within group effects as opposed to between group effects. But opponents to placebo use in psychiatric research contend that it is not actually that important to determine if a treatment is better than nothing (placebo), but whether if it is superior to the current standard. Also, it could be argued that it would always be unethical to have a placebo group if there is a known efficacious treatment available. However, sometimes, a placebo could allow for a lower number of subjects, ensure that any of the tested drugs are effective, or allow for shorter trials. RPCT are a good way of avoiding many of the biases encountered in research. It has been debated as to whether RPCT were always appropriate for other types of treatments such as psychotherapy, but they are generally accepted when it comes to drug development, even when there would be reasons to choose alternative models. What appears to be true is that RPCT are better to measure some types of treatments that others, namely short term treatments, drug versus placebo, and with quantitative outcomes.
Other challenges with RPCT are that they often are complex or costly and thus it is difficult to replicate trials. Therefore, it is far from certain that a given result can be replicated even if being replicable should be an argument of the scientific value and rigor of the research. This hypothetically allows for researchers to claim outcomes without the fear of being scrutinized by scientific confirmation. It is again the challenge of policing testimony (Cooper, 2007; Miller, 2000) . It is also clear that RPCT can be biased toward a desired outcome to some extent. Industry funded research is usually more positive than independent research, and we state this only to make the point that RPCT are not in and of themselves a guarantee of scientific value and soundness. It has even been argued that RPCT are in part responsible of the trust crisis in psychiatric evidence and practice: the methodology can be biased, they are rarely replicable, they are often tied to industry, researchers have been caught in scandals, and there is an appearance in RPCT of favoring research over the care of patients.
RPCT are also only as good as their generalization and they often exclude subjects who might be too young, too old, those with comorbid conditions, and those with other situations. They are usually short-term and they can choose to regroup versus separate illnesses if it is thought to better serve the desired outcomes. The question of psychiatric classification also has important implications in the sense that most RPCT are directed at single psychiatric diagnoses. But those constellations of cognitive, emotional and behavioral manifestations might be conceptualized or classified differently at another point in time. Also, trials using RPCT focused on a single disease state often fail to account for the fact that much of psychiatric experience is in the realm of co-morbidity and multiple syndromal states. With imperfect knowledge of psychiatric illnesses pathophysiology, it is challenging to actually recognize psychotropic drugs as diagnostically targeted drugs as opposed to drugs that are actually affecting some elements or symptoms of psychiatric conditions. A RPCT is a gold standard only as much as it is used to answer a valid question with a scientifically sound hypothesis. This allows us to discuss the question of equipoise. Equipoise is where the investigator is uncertain of the outcome of two results. The question is one in which testing between two specific conditions is needed to determine which is better or if there is any difference between conditions at all. If the equipoise concerns a matter important enough, it might be worth using resources and enrolling subjects in a study design powered to answer the uncertainty in question.
The use of placebo should generally be deemed less problematic in the case of add-on therapies, where every patient-subject receives at least the basic standard treatment. Maintenance treatment, where patients in remission are then randomized to receive active treatment versus placebo is another special type of design ethically. It has been proposed that patient-subjects may have to consent at various points during the phases of the trial. When studies are long-term, consent may also have to be obtained repeatedly.
Authors have argued for a middle ground (Emanuel and Miller, 2002) when it comes to using placebos ethically. Psychiatry probably falls in this middle ground window, where placebos can sometimes be justified for the reasons mentioned above. Aside from making sure the informed consent form is adequate, IRBs should keep an interest in evaluating if the study design is valid, and if placebos are justified whenever they are proposed in a trial. Clearly, the placebo arm does not mean that no treatment is given, especially in psychiatry. It only means that the active substance that is tested is not given. Frequent, complete and attentive followups are all important aspects of clinical treatment that are present in the context of clinical trials. This level of follow-up and care is facilitated by the resources that many research groups have in terms of staffing and time, and often cannot be replicated in community-based and traditional ambulatory care settings.
What are appropriate end-points for determining efficacy?
In the development of drugs in psychiatry, scores on various scales are often used as end-points for determining efficacy. Those scales can include lists of general or disorder-specific symptoms, signs, ratings by patients or researchers. They can also reflect more general considerations such as quality of life. Very few drugs are tested with respect to whether they are affecting specific brain circuits or regions, and oftentimes, little is known about how the drug creates its effect. Authors have argued that the choice of endpoints is one of the many ways researchers can bias the probability of getting positive results. For example, some scales insist more on sleep and appetite, which may enhance the antidepressant effect drugs independently of any effect on mood or interest. Scales putting more emphasis on cognitive aspects of depression might be preferred to validate psychotherapy focusing on cognitive distortions.
There is no lab test or type of neuroimaging that can provide an objective measure of improvement of mood, reduction in anxiety, or other such changes in innumerable affective states. To date, as noted above, the mainstay for determining drug efficacy has centered on scales which vary in their basic conception of a given psychiatric disorder and on how to quantify qualitative variables. An ongoing issue with this model is that it is difficult to translate 'x points of improvement on scale y' into a real-life correlate. Can the patient return to work? Is the patient now able to be independent with ADLs or IADLs with the improvement? In addition, there are issues to consider regarding patient-completed vs. clinician-rated scales; poor insight and limited ability for self-reflection and assessment is quite common across many psychiatric disorders (i.e. schizophrenia, severe depression).
In other fields, the important end-points sometimes are as blunt as mortality. This might not be entirely appropriate in psychiatry. Some said naturalistic studies have chosen as endpoints the time remained on a given medication, inferring that a change in treatment was a good proxy for determining efficacy or inefficacy. Regardless, the validity of studies is only as good as the validity of the end-points chosen. All scales presumably have their limits. Should patients be the ones to determine what constitutes an effective treatment or what constitutes a significant clinical outcome whether it is symptom reduction, general function, satisfaction, or the like? This challenge can be mitigated by including various end-points in research protocols. Then, the respective value of each point of view can be debated.
There are some general principles of measurement that could be used to improve the quality of studies. One general approach would be to use multiple points of outcome measurement via the use of eDiaries completed by subjects or having multiple points of follow-up (Jhaveri and Lee 2007) . This data can then be used to conduct area under the curve (AUC) analyses. Such approaches are more robust and minimize fluctuations on scales that can come from single point analyses. In addition, well respected statisticians like Helena Kraemer have advocated for investigators to look at outcomes using Number Needed to Take (NNT). This is analogous to Number Needed to Treat but calculates how many individuals are needed to see a given outcome. This type of statistical approach better evidences effect size of the treatment (Kraemer and Kupfer 2006) .
From a study design point of view, different valid methodologies of statistical analysis may be used, which on the other hand present with different ethical questions. Superiority versus noninferiority design is one such choice which has implications when it comes to justify resources and risks for participants. Is it of any scientific or clinical value to determine non-inferiority? It has been argued that sometimes, a non-inferior treatment, and even a less effective, but still more effective than placebo treatment, may be worthwhile to identify. Patients with the same psychiatric diagnosis may in fact be very heterogeneous in their presentation and response to treatment. Sometimes, different side effects profiles may justify the use of an otherwise similar or even less effective drug. This has in fact been the case with most antidepressants and antipsychotics developed since the 1990s.
Active comparator studies
Active comparator studies have the advantage of providing treatment to all subjects in the research. Unfortunately, most of the time, they are aimed at proving non-inferiority. This has been described as trials for "me-too" drugs. These trials are at risk of being powered just enough to show no significant difference between treatments. Also, if they are aimed at showing superiority, they are at risk to require more subjects than would a study against placebo since the difference, if any, is to be smaller. They might expose more subjects to risk than would be needed in a RPCT due to larger samples and broader exposure to active ingredients. (TORDIA) . These trials share a core in seeking to ascertain best practices for subpopulations of individuals suffering from psychiatric disorders. They all used standards for treatment that were generally accepted at the time the study was designed. Many of these studies changed practices and continue to impact care.
Should non-pharmacological interventions be in clinical trials?
Psychological treatment may be one of those things that are less amenable to study within a randomized control trial framework. So, it brings a set of special considerations. From an ethical perspective, the study design should be scientifically adequate to allow valid inferences. Again, the choice of end-points may be biased by what the authors want to demonstrate (choice of scale with neurovegetative elements, or cognitive elements). The length of the trial may favor some treatments over others, unless outcomes are general, in terms of general satisfaction or other such criteria.
On one hand, it may look as though a non-pharmacological arm is a desirable thing in a study design, since it is often one of the options that should be weighed in clinic. However, it is not necessarily clear if both types of treatments can be validly compared in the same trial, using the same end-points and the same time frame unless the trial includes various end-points and a flexible appropriate time frame, which is not always possible.
A better approach would be to encourage the incorporation of non-pharmacological interventions (when appropriate) into the design of drug trials. One example of this type of design was done for the assessment of adjunctive use of divalproex for treating aggression in children with stimulant-refractory ADHD (Blader et al., 2009 ). This trial included weekly behavioral therapy for all subjects, and the drug intervention was added above this baseline of treatment. The investigators risked reducing the effect size of their medication due to the potential potency of the behavioral intervention, but the design is far more ethically justifiable and appropriate (Steiner and Karnik, 2009) given the multiple interventions being done which fundamentally increase the safety of the child and potentially lead to a more rapid resolution of symptoms. This type of study also sets a benchmark for how clinicians can combine medications and psychotherapy for maximum effect.
Funding of trials
Funding is often a challenge in research. There are important implications in psychiatry relating to who is funding research. The mere fact that industry is first and foremost in the business of making money, and not of making good science, should raise some concern. But, if good science is a prerequisite to patenting drugs and selling them, it could also be argued that this does not raise any concern at all given the right legislation. Another way to put it: if scientific standards are regulated and checked by the appropriate authorities (FDA regulated, IRBs approved and so on), then only satisfying protocols should be accepted whenever human subjects are required, and source of funding should not be an issue at all.
Unfortunately, the issue it is not that simple, and funding does bring many ethical considerations into the development of drugs in psychiatry. In psychiatry, and elsewhere, being in the business of developing drugs often means also commercializing diagnosis. As we have pointed out, this in itself can be problematic if diagnostics are classified in a way that lacks validity in any way. New paradigms, new ways of understanding the field of mental illness, and novel ways to treat dimensions of illnesses are unlikely to come exclusively from industry funded research which is largely aimed at marketing and patenting drugs for recognized diagnostic categories.
We believe that the key is to know what to expect from industry-sponsored research and help shape its contours. It should be recognized that industry is not the only responsible party in the design and execution of clinical trials À researchers, government, and the public all have a stake in this process. The move toward patient-centered outcomes research holds much promise in bringing these parties together to chart useful research questions and approaches to trials that will not only help outline appropriate measures for clinical trials but also can examine present pharmaceutical through a comparative effectiveness lens.
Something ought to be said about study design bias and publication bias, for which industry funded research is thought to be more at risk than independent or exclusively academic funded research. The task of IRBs can certainly become extremely complicated if they are to identify each possible bias in protocols aiming at obtaining certain results instead of useful and valid scientific knowledge. One might think that independent investigators are immune to such biases, but humans are often less than perfect and are at risk to focus on positive results at the expense of more valid results. Positive papers tend to be published more than negative ones. There may be a tendency to spin positive results from a study with multiple publications with the same results. Length of trials, dosage of comparators, type of analysis, and so forth are all ways one can bias the results he expects to obtain. Industry funded research is perhaps at greater risk, but certainly not exclusively at risk for these aspects.
Considering funding new drugs in psychiatry exclusively with public money is probably not realistic in the short term, and does not give guarantees of research quality. Rather, it primarily minimizes one type of problem. Money is not the only thing that can bias the way research protocols are written. The tendency of positive papers being published more often than negative papers can impact the ways authors manage their choice of end-points. The ClinicalTrials.gov website created by the U.S. Department of Health and Human Services was designed to bridge this divide and maintain an archive of data and studies for all clinical trials undertaken in the U.S.
Consideration could be given to changing the structure of funding of clinical trials in the U.S. At present the responsibility for paying for trials rests with pharmaceutical companies. This gives the companies and the investigators who work closely with them a strong incentive to design trials in a manner that lends itself to promoting the product rather than testing it relative to existing interventions. It is important to note that recent shifts in the funding landscape have moved a great deal of primary and basic research into the hands of small biotechnology companies. Many of these companies use venture capital and other donor funds to support high-risk (meaning high failure rate) research. The model that has emerged is that after these small companies develop their new product they hope to court a larger pharmaceutical company into some type of relationship so that their product can be developed. This leads to mergers and buy-outs, and money that could otherwise be used to support research is harvested by various investors and risk-takers in these processes.
The FDA, with congressional action, could re-design the structure of trials so that Phase I and II trials would be the responsibility of the pharmaceutical company, and that Phase III and IV trials would be conducted by the National Institutes of Health. Under this structure companies would pay into a common fund to support the Phase III and IV trials. Such a structure could mirror the way that the Federal Deposit Insurance Corporation (FDIC) works to insure individual banks by charging a fee proportionate the deposits held by the bank. Similarly, pharmaceutical companies would pay a portion of their revenue for drug sales into a common fund that supports clinical trials for the entire system of drug trials. Such a structure would provide several ethical advantages over the present system. First, it would allow most physician-scientists to more directly propose designs of trials in a rigorous fashion. Second, it would provide a stable source of funds for the long-term study of medications. Third, it would free pharmaceutical companies from the direct responsibility for trials and likely reduce their exposure to costly litigation that results from side effects of medications that are discovered later in the drug development process.
Suicide risk assessment & management in research trails
When conducting trials of novel drugs, it is necessary to have appropriate ways of managing risks. Risk can be varied, whether it is for suicidality or medical complications. If a complication is foreseen, clear ways to detect it and manage it, via follow-up questionnaires, rescue medication, and the like should be in place. There should also be provisions for unforeseen complications to be rapidly identified, evaluated and managed. Authors have made the point that a serious complication and even death during a trial does not mean that the trial was unethical at the outset. The ethical point is that research protocols need provisions for such events, and the safety of patients must clearly come before drop-out rates. There is also a need for safety overview when there are multi-site trials to make sure that unexpected complications trends are rapidly compiled and decisions can rapidly be made whether the whole trial needs to be stopped.
One such complication in psychiatry is the possibility for increased suicidality (since suicidality is a common feature of conditions such as depression and for which many drugs are studied). There are already black box warnings for children and adolescents, and it has also been reported in adult patients that suicidality could be increased in certain individuals. Authors have reported that suicides and suicide attempts generally are not increased in placebo arms of clinical trials (Gibbons et al., 2012) , but it is equally important to be wary of increased suicidality in the trial arm receiving the active treatment.
Suicidality is a very important aspect of many psychiatric disorders, which needs to be studied. Unfortunately, many studies of psychiatric treatment intentionally exclude individuals with suicidal ideation. The logic is that these individuals may need a higher level of care and it might be ethically unjustified to risk having these individuals in a placebo arm if they randomized to this situation. As a result, suicide continues to be an understudied domain in clinical drug research. As much as it is reassuring to see that placebo-patients in clinical trials are generally not at higher risk of suicidality (Khan et al., 2000) , it is a scientifically and ethically daunting problem to find ways to study such an important aspect of psychiatric illness in clinical trials, since one would actually hope to find a clear difference in suicidality in the clinic when using psychotropic drugs. Such data would have to be gathered in other ways, e.g. in observational studies, and with less robust conclusions.
Special populations
Special populations pose special ethical concerns in psychiatric research and development of new drugs. Some populations are largely not decisional (meaning that they lack the ability to make independent decisions about their care) but still often need pharmacological treatment. It is daunting to generalize the use of drugs to populations that have not been properly studied. Patients with comorbid conditions are also frequently excluded from trials. Naturalistic studies sometimes try to overcome those difficulties, but can become imprecise in their results because the subject pool is too diverse.
As a general rule, it has been argued that whenever a research question can be answered on a non-human subject, it should be. Likewise, whenever it can be answered on subjects with full decisional capacity, it also should be. This standard has discouraged research on the unique needs of certain vulnerable populations. Clinical trials need to be done on many of these subpopulations, and the FDA has encouraged trials in children, in particular, by using an extension of patent protection authorized by Congress.
On this topic, while patients in psychiatry are sometimes lacking decisional capacity, it has been demonstrated that psychiatric disorders do not determine a person to be incapable of decision-making. Even depressed and psychotic patients can make decisions, including decisions to participate in clinical research for the development of new drugs (Appelbaum and Roth, 1982) . Developing drugs for psychiatric patients without or with diminished decisional capacity is certainly a challenge, but arguably a necessary task, lest some subgroups of the population are never studied as they should be in clinical research for the development of new drugs.
Children & adolescents
It has been proposed that whenever possible, research should be done on decisional adults. But it is also clear that when it comes to drugs, children are not the equivalent of small adults (for pharmacokinetic and pharmacodynamics reasons) (Kölch et al., 2010; Vitiello, 2003) . Their brains and metabolism are still developing. There was recent concern about increased suicidality with the use of SSRIs especially in child and adolescent populations, resulting in a black box warning by the FDA. These are ethical challenges of doing good science in developing drugs for children. On the one hand, it appears unethical to develop or market psychotropic drugs for children that are not actually tested on children at any point in the process. On the other hand, when is it ever ethical to actually test something on children?
Parental or guardian consent is certainly required in most contexts where research is being done on children but it is not enough. The risks of the intervention and the value of the research proposed have to be considered, and there are matters for which a child is not apt to consider. Potential individual benefits are usually not the main argument in deciding whether a research protocol is actually ethical. The benefits are better considered societal. In reality, there is often what is called an individual potential benefit assessment that lies behind the decision of participating in research. Only then is a decision reached by the subject or their representative, weighed with potential harm and what is also known about the risks and benefits of the standard of care, if any. The question remaining is whether the protocol is good, safety assessment and monitoring satisfying and consent process adequate. Then, participation in the research can be proposed. In the special case of children, it is their parents or representatives who are going to actually have the final say in the participation, unless there is a categorical explicit refusal. One can wonder if there is any level of risk that is absolutely incompatible with even actually proposing the research. The acceptance of minimal risk is generally accepted, (i.e. the probability and magnitude of physical or psychological harm anticipated in the research are not greater in and of themselves than those ordinarily encountered in daily life, or in routine medical, dental, or psychological examinations).
In children, it can be difficult to judge risk in regards to psychiatric illnesses because the impacts of these illnesses are unclear and subject to difficult timelines of progression. Clearly, children facing diseases like cancer have had to assume risk as the array of pharmacological treatments in the field has developed. The impact of cancer and its progression while often uncertain has a generally predictable cadence which allows clinicians and the children's families to understand risks better. In contrast, the impacts of childhood psychiatric illnesses are very real but much less predictable. Rates of completed suicide among children and adolescents have reached new highs and yet the causal linkages to specific psychiatric disorders remain unclear. Therefore it can be difficult to judge relative risk in a clinical trial for a new therapeutic since suicide remains a relatively rare event in large populations. Similarly, it can be very hard to predict the life course impact of childhood psychiatric illness. How much of an individual's success or failure in later life may be due to psychiatric morbidity in childhood? While we understand some of these phenomenon on a population basis, the transferability of this knowledge to specific risk-benefit analyses for clinical trials remains difficult and uncertain because of the multiplicity of factors that impact individuals.
Many of the ethical challenges described for developing psychotropic drugs for children also apply for adolescents. Yet, adolescents are more apt to understand the risks and benefits of a research project, and their willing to participate probably should have more weight. On the other hand, it is known that adolescents' judgment is still developing, and that they can be impulsive in their decisions. As long as research is minimal in risk this discussion may be of little consequence. It goes without saying that IRBs should not authorize a research protocol that is unacceptable. Perhaps the hardest thing to determine is whether a research design is suitable for proposing participation to parents and adolescents. This challenge exists for all research protocols irrespective of the potential subjects' age. However, the cut-off presumably must be appropriately adjusted for age such that there is low risk for children, adolescents, and those without decision-making capabilities and appropriately higher risk for decisional adults.
Elderly
Concerning elderly people, most of the ethical challenges are related to decisional capacity. Elderly patients, in and of themselves, are not unable to make decisions. But cognitive problems, more so when they are moderate to severe (Dunn et al., 2006) , are certainly subject to give decisional difficulties. It has been shown that even mild cognitive deficits may actually impair decisional capacity, for example, in persons with Alzheimer's disease (Karlawish, 2008 ). Yet much research is needed in the treatment of psychiatric illness in the elderly, which cannot simply be inferred from knowledge in the general population. So whenever possible, clinical research is preferably done with competent adults. Therapeutic and toxicity intervals, pharmacokinetic and pharmacodynamic considerations often require special attention in the elderly, but can probably be studied in decisional individuals. When the questions concern disorders or aspects of disorders that affect decisional capacity, there may be no other choice but to study patient-subjects with substituted consent.
Special precautions should be taken both with substitutes and patient-subjects. Categorical refusal ought to be respected and assent obtained if possible. Special educational material and interventions should be used to enhance decisional capacity whenever possible. Therapeutic misconception ought to be addressed.
Research during pregnancy
A pregnant patient with a psychiatric disorder presents special and unique challenges pertaining to psychiatric drug utilization and development. In the first, there are two beings that must be considered, one which is capable of making autonomous, and (hopefully) informed decisions, and the other a passive recipient of such choices and their consequence(s). A tension erupts because what may be optimal for the mother may confer risk to the fetus; and that which reduces risk or is optimal for the fetus, may result in under treatment or lack of treatment for the mother.
A massive global effort is underway to identify which psychotropic drugs are (or are not) safe for use during pregnancy and to measure the benefit(s) the mother derives from taking the medication. Whilst the earliest concerns have been focused on drug induced physical malformations in the fetus, in recent years there has been growing concern for possible enduring neurobehavioral adverse effects that may not show up for years.
While the effort to determine which psychotropic drugs are safer in pregnancy is ongoing, there are a plethora of programs that try to summarize recent relevant literature, provide clinicians with valuable data or points to consider, and in some cases provide clinical or decisional support to physicians and/or patients to help both parties cooperatively navigate this complex terrain. Programs such as TERIS (Teratogen Information System), OTIS (Organization of Teratology Information Specialists), and MOTHERISK, are but a few of such programs. There are also a number of international conferences held annually, attracting clinicians and researchers from around the world to discuss and debate this topic.
While it is beyond our scope to review the vast literature on the subject of psychotropic drug use during pregnancy, we reference a select number of research investigations throughout the discussion to establish a platform to explore the host of ethical issues and quandaries in this branch of perinatal mental health. The use of anti-depressants has received much international attention, as depression is one of the most common psychiatric disorders not just worldwide, but it is also common in pregnancy and the post-partum period (Melville et al., 2010; Gavin et al., 2005) . A study report published by Cohen et al., in the February 2006 issue of the Journal of the American Medical Association, reported results of their investigation, which examined rates of relapse to major depression in two cohorts of women. One cohort continued their pre-existing anti-depressant regimen during the entirety of the pregnancy, and the other cohort did not. The study was prospective, naturalistic study, not a randomized trial. All study participants were in a state of complete remission regarding their history of major depression, upon entering the study. The overall rate of relapse to major depression was 43%, however, those women who chose to stop their medications had a relapse rate of 68% whereas those who did not relapsed 26%. Of course, the reality is far more complex than percentage values; but there is no crystal ball, so to speak, as to which patient will or will not suffer a relapse once medication is stopped (Cohen et al., 2006) . This study had a significant influence on the field of perinatal mental health, and also served to debunk a rather longstanding belief (myth) that hormonal changes in pregnancy, in their own right, protect expectant mothers from major depression.
One ethical issue emerging from the findings of this study -if one believes the research methodology was rigorous, and therefore the results to reflect a true clinical effect of anti-depressants -is that there is a significant risk of relapse if medication is discontinued. The decision to continue or discontinue a medication hinges on an analysis of the benefits and risks of each of those options, and such analysis by definition must account for the severity of the patient's symptoms during prior bouts of depression. It must also take into account the level of functioning the patient must maintain in order to meet current and future obligations, and the consequences that would emerge for failure to meet those responsibilities. Obviously, the assessment would also need to factor for any possible deleterious effects of the drug on a developing fetus. There appears to be a proverbial 'Catch-22 0 : if the mother goes untreated/is ineffectively treated/or is under-treated, then there are sequelae for both mother and fetus. If the mother is treated with a medication, she may or may not improve, and either way the fetus is exposed to possible insult from a xenobiotic. This 'begs' a number of questions: 1) What is the physician's role and responsibility on giving medically sound, evidence-based advice to the patient? 2) In what circumstances should or must a physician intervene in order to protect a fetus, the mother, or neonate? 3) Is it ethical for there to be forced treatment with psychotropics in pregnancy -under any circumstances, and if so what are those circumstances? 4) Should the use of psychiatric medications on an emergency basis be handled differently in pregnant patients? 5) How should physicians respond to requests for treatment with a psychotropic by pregnant patients or patients who have stated that they are in process of trying to start a family? For a moment, consider a female patient who has only mild symptoms of depression, is planning to start a family with her husband imminently, and requests an antidepressant after refusing alternative treatments. Is it the patient's right to choose the treatment in this specific case? There are no simple answers to such questions, and certainly we do not purport to have a secret antidote to these consternating moral dilemmas. Nevertheless these questions must be asked.
Just as there are studies whose findings support considering use of psychiatric drugs in pregnancy, there have been drug advisories, and studies that argue against the use of psychotropics in pregnancy. The FDA, in 2005 issued a warning about the use of paroxetine and risk of fetal cardiac defects. Some would argue that more recent studies (see Norwegian Mother and Child Cohort Study; Nordeng et al., 2012) have undermined the validity of that warning. In another example, a review paper published by Domar et al. (2013) declared that antidepressant use during pregnancy is associated with increased risks of miscarriage, birth defects, preterm birth, newborn behavioral syndrome, persistent pulmonary hypertension of the newborn, and possible long-term neurobehavioral effects. The investigators sought to analyze the safety and efficacy of SSRIs in fertile women. These contradictory conclusions from large studies or review papers present significant ethical challenges for clinicians and policymakers who are trying to care for pregnant women.
While the use of antidepressants during pregnancy has received much international attention, it must not be forgotten that there are other, equally important disorders that can develop before, or during pregnancy and in the post-partum period, such as schizophrenia, bipolar type I disorder, substance use disorders. We will briefly consider one clinical example here to demonstrate a point where perhaps the literature can be argued to be less controversial about a psychotropic medication ameliorating a psychiatric disorder. The medications used to treat these, have a much wider range of receptor activity and very significant side effect profiles in adult physiology, where the organs and biometabolism have reached their terminal maturation.
There is yet another scenario that raises ethical issues, this time in the domain of treatment of substance use disorders. Consider a patient with a serious heroin use disorder. There is a wealth of evidence substantiating methadone maintenance treatment for markedly reducing complications arising from intravenous heroin use (HIV, Hepatitis C) and associated social sequelae (job loss, financial, failure to meet role obligations). Would it better for a pregnant patient with a heroin use disorder to receive methadone with a chance for social, financial, and psychiatric, recovery and reduce the chances of becoming infected with HIV, or to have a known much higher risk of being involved in drug use and not expose the fetus to the methadone which has not been identified as a major teratogen.
One of the greatest challenges in psychotropic drug use during pregnancy is determining whether it is in fact the drug or other factors that increases the risk for birth defects. Many psychiatric disorders result in altered behavior, and have effects on the neuroendocrine system. It remains to be elucidated whether the associated pathophysiologic changes in the mother, themselves adversely affect organogenesis in the fetus. It is also quite possible that some unknown behavior, possibly common to a specific disorder (e.g. depression) may be common among women suffering from depression and that behavior may in its own right confer additional material risk for birth defects.
To address some of the more pressing questions about psychotropic drug use in pregnancy, researchers are trying to conduct studies where the number of patients and controls are in the thousands or tens of thousands. A number of countries, particularly Nordic Countries, possess national registries that have been in place for years, for the purpose of acquiring long-term epidemiologic data, and this has come to include women who take psychiatric medications during pregnancy. This has provided a great boon to the discipline of psychopharmacology in pregnancy, as many studies have been plagued by small numbers of participants, thereby making the results prone to bias and requiring a large signal to detect any adverse effect of a drug.
The vast majority of research occurs in the form of prospective observational studies where women who elect or refuse to continue or start a drug to treat a diagnosed psychiatric disorder, and are then followed prospectively to determine fetal outcome (birth defects, difficulty with adaptation at birth, and so on).
Another very common type of research investigation is mining data from national registries, which are particularly common in the Nordic countries. While it has limitations, perhaps this is not only the most feasible, but the most ethical manner in which to study the use of psychotropics in pregnancy. As an example, the Norwegian Mother and Child Cohort Study (Nordeng et al., 2012) reported that of 63,395 only 1.1% (699) of them reported using an anti-depressant during pregnancy. After adjusting for the level of maternal depression, lifestyle factors and sociodemographic factors, no association was found between in utero SSRI exposure and any of the following outcomes: pre-term birth, low birth weight, strongly increased risk for fetal malformations.
Unfortunately, pharmaceutical science is not at a point where we can predict, from molecular structure or in vivo biological activity, the potentiality of a drug to be a teratogen with any degree of certainty. Thus novel drugs are not synthesized with the intention to be safe in pregnancy, but may end up being used during pregnancy because all other treatments have failed, and the situation is dire enough to justify its use. Perhaps this is the best that can be done with current scientific knowledge and understanding. In the meantime, it will be important to remain vigilant about the multiple ethical issues described herein, pertaining to drug use during pregnancy.
Research concerning prisoners
Research on prisoners was one of the issues considered during the Nuremberg trial. Is it ever ethical to do medical and specifically psychiatric research on subjects that are also prisoners? Since prisoners constitute a considerable population in the USA and elsewhere, it would seem very important that this population be a focus of rigorous scientific research for psychiatric treatment study (Gostin et al., 2007) . Research on prisoners, if for the benefit of prisoners, is potentially ethical. It is well recognized that mental disorders are very prevalent in prisons and there may be specific needs for research among prisoners. Research to develop scientific knowledge for conditions affecting both prisoners and the general population could also arguably fairly be shared in its burdens and benefits on both populations. Needless to say, those populations are not static and there is a movement of individuals between both of them, making it even more acceptable from an ethical point of view.
One major ethical problem would be the selection of prisoners for drug development in a way that would make them unjustly burdened by the risks and inconveniences of the research compared with the rest of the population subject to benefit from the research. There are precedents of terrible abuses on coerced individuals in the name of science, resulting in the code of Nuremberg in 1947. A number of factors may draw investigators to consider working with subjects who are incarcerated: 1) The subjects are captive and at a known, fixed physical location, and easy to follow; if needed, movement of the subject can also be determined as detailed records of movement between facilities are kept. 2) There is a high prevalence of mental disorders in the prison population. 3) Inmates have regular routines, an externally controlled diet, and this standardization is an asset. Concurrently, it is these same factors that could lead investigators to target prisoners in an unbalanced manner for research. Otherwise, to the question whether it is ever ethical to develop and test drugs on prisoners, the same standards should probably apply with some special precautions and provisions. In this case, the question of incentives to make probation, or special treatment inside prison would have to be addressed. It should be made explicit that the research will not affect probation decisions, nor will it give access to advantages in the prison, except maybe those related to the strict necessary medical follow-up. Time in nursery, access to care, even in the explicit and disclosed context of clinical research for drug development, could prove sufficient advantages for some individuals to volunteer for research in ways they would not have done outside prison. Research should never be seen as a way to give back or pay back, or as part of the prison burden. That is to say, that the incarcerated person's punishment must always be confined to the restriction of liberties and assignment of duties as were determined in a court of law, and is never to include participation in medical research. The consequences of having broken the social contract, repentance, reparations, and rehabilitation must be kept, at all times, separate and distinct from a decision (or offer made) to become a research subject.
Relating to the subject of coercion is the challenge of offering appropriate compensation to subjects who are in the penal system. Compensation that is excessive could easily be interpreted as a bribe or inducement, and insufficient compensation might imply that because the subject is incarcerated the value of the subject's participation is less. At some level, it becomes impossible to divorce incentive from the individual's desire for freedom or possible relief from burdens associated with his or her imprisonment, even if there is no monetary compensation or compensation with objects that have little or no monetary value. The visit to a physician, which removes the person from his cell and the social milieu, even if only for a brief period, may be incentive enough, and it is impossible to completely remove this kind of influence.
Confidentiality of treatment is a major obstacle in prison settings. There is no way to conceal a guard approaching a prisoner's cell and escorting the prisoner off the cell-block. While the exact purpose may not be known, the routine would soon make itself transparent, and draw attention to the subject. This attention may have unintended consequences À e.g. coercion by other inmates to reveal the nature of the 'special privilege' or threats of physical harm to disclose personal (health or other) information. Moreover, there is also the issue of privacy of information and security of personal health information data. Unintended, accidental breeches of data are somewhat commonplace. From a research ethics vantage point, it must be considered how such a breech would impact the prisoner's daily life.
An interesting dilemma arises when a study drug may in fact alleviate the cause or symptoms of a psychiatric disorder that is arguably responsible for the subject having been incarcerated in the first place. How should the researcher respond when the subject asks, "will the drug help me [get out of here]?" While there may be no specific link between the study and early parole for example, one is hard pressed to dissociate the well-known relationship between good behavior and the rewards afforded to prisoners for same, including sentence reduction and release. Even if the investigator is rigorous and clear in delineating the limit of benefits of study participation, it is the perception of the subject À regardless of its veracity À that ultimately will influence a decision to participate or not.
Conclusions
It is essential to identify, recognize and address ethical challenges in the development of drugs in psychiatry. Ethical challenges are not limited to the quality of informed consent and placebo use. Alternative models, clinical innovation, specific considerations for special populations are all important aspects to consider. Ethical challenges also concern the quality of study designs, protocols and methodology, because it is an ethical imperative to make useful, valid and sound research to justify the human time, cost, risk and use of limited resources. Industry and funding are obvious sources of ethical questions, but cannot be identified as the sole ethical problem of drugs development in psychiatry.
It has to be recognized that links with industry certainly contribute to a trust crisis and the climate of suspicion against psychotropic drugs, trials of new drugs, the marketing of diagnosis, etc. Recent scandals in drug development certainly demonstrate this point. But a critique exclusively limited to industry funded research, and an automatic identification of industry as the source of ethical problems in the development of drugs in psychiatry probably misses less obvious but equally important ethical challenges. Also, industry funds, if used for research that is both meaningful and profitable can add important data to our knowledge base.
It is likely that people with a variety of interests ought to be invited to comment on important scientific questions to be answered, the procedures, the acceptable risks and burdens justified by it, and the types of compensation. Researchers, the public, government, industry, and IRBs should collaborate in their efforts to promote ethical development of drugs. Since research is done by imperfect researchers, published by imperfect publishers, funded by imperfect funders, since various and sometimes conflicting interests may and do converge in the development of drugs in psychiatry and elsewhere, since the needs are great for better understanding and treatment of mental illnesses, ethical challenges are and presumably will remain a crucial topic in the years to come.
It would probably be of little use, and slightly dishonest, to call for ideal and uninterested research. Motivation to do the hard work of clinical research may come from more than one source. Researchers are rarely ideal knowledge-seekers (Cooper, 2007) . They have interests (careers, grants, prestige, money, special preferences and opinions) that may bias their work. Governments and other authorities also have interests, which may be biased in many ways (pressures by lobbies, elections, short term results, etc.). General population, subgroups of the population, even groups of individuals with mental disorders with obvious interest in the development of drugs in psychiatry may push the research in ways that are not the best scientifically, etc.
It has been argued that regulations and current marketing process may have impeded some historically useful and fruitful ways to make important discoveries of new drugs or new applications for known drugs. There is an interesting history of innovation and serendipity in the development of drugs in psychiatry, and a tradition of close contact between careful individualized care and observation, and links to research questions and advancement, psychopharmacological research being both a link to pathophysiological understanding and therapies.
Some researchers may deem the confidence crisis overamplified but they nonetheless should not ignore it. There is enormous potential of significant knowledge and therapeutic advancement that can be compromised if research and development of psychiatric drugs is seen merely as a sophisticated marketing tool for patenting drugs without real merit other that satisfying minimal regulatory standards.
The field is likely to expand and grow in the coming years. The use of genetic markers, the introduction of personalized medicine, patient-centered outcomes research, and the ongoing tension over funding of trials are likely to be key factors in the years to come. Many of these considerations will raise new ethical challenges. We believe that innovations in how trials are designed to better reflect practices in clinical settings, expansion of the transparency of informed consent processes, new attention to suicidality, and care in working with vulnerable populations could all strengthen the field and help support the common goal of developing sound therapies that alleviate psychiatric suffering.
